Paranasal sinus carcinoma
diseaseOn this page
Also known as accessory sinus canceraccessory sinus carcinomacancer of paranasal sinuscarcinoma of accessory sinuscarcinoma of paranasal sinuscarcinoma of the accessory sinuscarcinoma of the paranasal sinusmalignant neoplasm of paranasal sinusmalignant paranasal sinus neoplasmparanasal sinus cancer
Summary
Paranasal sinus carcinoma (MONDO:0000380) is a cancer (an umbrella term covering 8 Mondo subtypes) and 11 clinical trials. Top therapeutic interventions include ipilimumab. A subtype of bone carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 8 Mondo subtypes
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | paranasal sinus carcinoma |
| Mondo ID | MONDO:0000380 |
| DOID | DOID:0050619 |
| NCIT | C6014 |
| UMLS | C0854995 |
| MedGen | 167751 |
| GARD | 0009354 |
| Anatomy (UBERON) | UBERON:0001825 |
| Is cancer (heuristic) | yes |
Also known as: accessory sinus cancer · accessory sinus carcinoma · cancer of paranasal sinus · carcinoma of accessory sinus · carcinoma of paranasal sinus · carcinoma of the accessory sinus · carcinoma of the paranasal sinus · malignant neoplasm of paranasal sinus · malignant paranasal sinus neoplasm · paranasal sinus cancer · paranasal sinus carcinoma
Disease family
This is a subtype of bone carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone carcinoma › paranasal sinus carcinoma
Related subtypes (6): bone squamous cell carcinoma, adamantinoma, growth hormone-producing pituitary gland carcinoma, osteosarcoma arising in bone Paget disease, pituitary adenocarcinoma, metastatic carcinoma in the bone
Subtypes (8): maxillary sinus carcinoma, frontal sinus cancer, paranasal sinus sarcoma, ethmoid sinus cancer, sphenoidal sinus cancer, paranasal sinus adenoid cystic carcinoma, paranasal sinus squamous cell carcinoma, paranasal sinus mucoepidermoid carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE2 | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT05075980 | PHASE2 | ACTIVE_NOT_RECRUITING | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study |
| NCT03096808 | PHASE2 | COMPLETED | Adaptive Radiotherapy for Head and Neck Cancer |
| NCT03274414 | PHASE2 | COMPLETED | A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages |
| NCT05114707 | PHASE2 | UNKNOWN | Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses |
| NCT02012699 | Not specified | RECRUITING | Integrated Cancer Repository for Cancer Research |
| NCT05614375 | Not specified | RECRUITING | Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus |
| NCT03049358 | Not specified | TERMINATED | Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer |
| NCT04788264 | Not specified | COMPLETED | Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment |
| NCT04985357 | Not specified | WITHDRAWN | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs |
| NCT05992610 | Not specified | UNKNOWN | Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| IPILIMUMAB | 4 | 1 |
Related Atlas pages
- Drugs: Ipilimumab